SB505124 (SB-505124)是一种转化生长因子β I型受体(TGFβR) ALK4/5/7的选择性抑制剂，抑制ALK4和ALK5，IC50分别为129 nM和47 nM，但不影响ALK1/2/3/6活性。
参考文献
1.DaCosta Byfield S, et al. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2004;65(3):744-52.
2.Misumi S, et al. Enhanced neurogenesis from neural progenitor cells with G1/S-phase cell cycle arrest is mediated by transforming growth factor β1. Eur J Neurosci. 2008;28(6), 1049-1059.
3.Hu T, et al. Reactive oxygen species production via NADPH oxidase mediates TGF-β-induced cytoskeletal alterations in endothelial cells. Am J Physiol Renal Physiol. 2005;289(4).
4.Marini KD, et al. Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy. Sci Transl Med. 2018;10(451): eaat3504.
冰袋运输。粉末直接保存于-20℃，有效期2年。建议分装后-20℃避光保存，避免反复冻融。
